Zenas BioPharma initiated with a Buy at Jefferies

Jefferies analyst Roger Song initiated coverage of Zenas BioPharma with a Buy rating and $35 price target Zenas is a late clinical stage biotech focused on inflammation and immunology-directed opportunities, the analyst tells investors in a research note. The firm says the company’s lead asset is “first-in-class” obexelimab with a differentiated inhibitory mechanism of action for various B-cell driven autoimmune diseases.